Cell death mechanisms induced by cytotoxic lymphocytes

Cellular and Molecular Immunology

Volumn 6, Issue 1, 2009, Pages 15-25

  Chavez Galan L ^a   Arenas Del Angel, M C ^a   Zenteno, E ^b   Chavez R ^b   Lascurain, Ricardo ^a,b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Apoptosis; Cytotoxic cell; FasL; Granule dependent exocytosis; TNF

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GNLY PROTEIN, HUMAN; GRANZYME; PERFORIN; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; FAS ANTIGEN; GRANULYSIN; GRANZYME A; GRANZYME B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; CASPASE 3; CASPASE 8; CYTOCHROME C; MANNOSE RECEPTOR; NATURAL KILLER CELL RECEPTOR; REACTIVE OXYGEN METABOLITE; SINGLE STRANDED DNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXOCYTOSIS; HUMAN; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; REVIEW; CD8+ T LYMPHOCYTE; CELL DEATH; CYTOTOXIC LYMPHOCYTE; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MOLECULAR INTERACTION; PROTEIN CROSS LINKING; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL GRANULE; CELL SURFACE; CYTOLYSIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HOMEOSTASIS; IMMUNE RESPONSE; INTERNALIZATION; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OUTER MEMBRANE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; TARGET CELL;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; EXOCYTOSIS; FAS LIGAND PROTEIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; MODELS, BIOLOGICAL; PERFORIN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65549091573     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.3     Document Type: Article

References (142)

1. Walsh KB, Lanier LL, Lane TE. NKG2D receptor signaling enhances cytolytic activity by virus-specific CD8+ T cells: evidence for a protective role in virus-induced encephalitis. J Virol. 2008;82:3031-3044.
2. Gullo CA, Hwang WY, Poll CK, Au M, Cow G, Teoh G. Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. J Immune Based Ther Vaccines. 2008;6:2.
3. Verhoeven DH, de Hooge AS, Mooiman EC, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol. 2008; 45:3917-3925.
4. Sirianni MC, Campagna M, Scaramuzzi D, et al. Control of human herpes vims type 8-associated diseases by NK cells. Ann N YAcad Sci. 2007;1096:37-43.
5. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood. 2008;112:708-710.
6. Maenaka K, Juji T, Nakayama T, et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem. 1999;274:28329-28334.
7. Sanni TB, Masilamani M, Kabat J, Coligan JE, Borrego F. Exclusion of lipid rafts and decreased mobility of CD94/NKG2A receptors at the inhibitory NK cell synapse. Mol Biol Cell. 2004;15:3210-3223.
8. Yu Y, Wang Y, Feng M. Human leukocyte antigen-Gl inhibits natural killer cytotoxicity through blocking the activating signal transduction pathway and formation of activating immunologic synapse. Hum Immunol. 2008;69:16-23.
9. Blaschitz A, Hutter H, Doin' G. HLA class I protein expression in the human placenta. Early Pregnancy. 2001;5:67-69.
10. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-729.
11. Mescher MF, Agarwal P, Casey KA, Hammerbeck CD, Xiao Z, Curtsinger JM. Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin Immunol. 2007; 19:153-561.
12. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929-941.
13. Abbey JL, O'Neill HC. Expression of T-cell receptor genes during early F-cell development. Immunol Cell Biol. 2008, 86: 166-174.
14. Le Drean E, Vely F, Olcese L, et al. Inhibition of antigen-induced F cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 1998; 28:264-276.
15. Masilamani M, Nguyen C, Kabat J, Borrego F, Coligan JE. CD94/NKG2A inhibits NK cell activation by disrupting the actin network at the immunological synapse. J Immunol. 2006; 177:3590-3596.
16. Lieto LD, Maasho K, West D, Borrego F, Coligan JE. The human CD94 gene encodes multiple, expressible transcripts including a new partner of NKG2A/B. Genes Immun. 2006; 7:36-43.
17. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998;8:693-701.
18. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4: 557-564.
19. Vance RE, Jamieson AM, Ranlet DH. Recognition of the class lb molecule Qa-l(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med. 1999;190:1801-1812.
20. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285: 730-732.
21. Kim DK, Kabat J, Borrego F, Samii TB, You CH, Coligan JE. Human NKG2F is expressed and can associate with DAP12. Mol Immunol. 2004;41:53-62.
22. Arlettaz L, Villard J, de Rham C, et al. Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CDS TCR aβ lymphocytes. Eur J Immunol. 2004;34:3456-3464.
23. Bhagat G, Naiyer AJ, Shah JG, et al. Small intestinal CD8+ TCR yS+ NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J Clin Invest. 2008;118:281-293.
24. Ortega C, Romero P, Palma A, et al. Role for NKG2-A and NKG2-C surface receptors in chronic CD4+ T-cell responses. Immunol Cell Biol. 2004;82:587-595.
25. Ota T, Takeda K, Akiba H, et al. IFN-y-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood. 2005;106:184-192.
26. Brand VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
27. Kaiser BK, Barahmand-Pour F, Paulsene W, et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol. 2005; 174:2878-2884.
28. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Set U S A. 2008;105:6696-6701.
29. Petrie EJ, Clements CS, Lin J, et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J Exp Med. 2008;205:725-735.
30. Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, Cosman D. NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;291: L222-231.
31. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor y-chain. J Immunol. 1999;162:5-8.
32. Tedla N, Bandeira-Melo C, Tassinari P, et al. Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Set USA. 2003;100:1174-1179.
33. Sloane DE, Tedla N, Awoniyi M, et al. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood. 2004; 104: 2832-2839.
34. Cho M, Ishida K, Chen J, et al. SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type IIFN production. Int Immunol. 2008;20:155-164.
35. Ju XS, Hacker C, Scherer B, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene. 2004;331:159-164.
36. Velten FW, Duperrier K, Bohlender J, Metharom P, Goerdt S. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol. 2004;34: 2800-2811.
37. Saverino D, Fabbi M, Glnotto F, et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol. 2000;165: 3742-3755.
38. Shiroishi M, Tsumoto K, Amano K, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA. 2003;100:8856-8861.
39. Shiroishi M, Kuroki K, Rasubala L, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA. 2006;103:16412-16417.
40. LeMaoult J, Zafaranloo K, Le Danfif C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005; 19: 662-664.
41. Chang CC, Silvia EA, Ho EK, Vlad G, Suciu-Foca N, Vasilescu ER. Polymorphism and linkage disequilibrium of immunoglobulin like transcript 3 gene. Hum Immunol. 2008;69:284-290.
42. Kim-Schulze S, Seki T, Vlad G, et al. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am. J Transplant. 2006;6:76-82.
43. Gleissner CA, Zastrow A, Klingenberg R, et al. IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Eur J Immunol. 2007;37:177-192.
44. Wilson MJ, Torkar M, Haude A, et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Set USA. 2000;97:4778-4783.
45. Kabalak G, Koch S, Dobberstein B, et al. Immunoglobulin-like transcripts as risk genes for autoimmunity. Ann N Y Acad Sci. 2007;1110:10-14.
46. Trowsdale J, Barten R, Haude A, Stewart CA, Beck S, Wilson MJ. The genomic context of natural killer receptor extended gene families. Immunol Rev. 2001;181:20-38.
47. Torkar M, Norgate Z, Colonna M, Trowsdale J, Wilson MJ. Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex. Eur J Immunol. 1998;28:3959-3967.
48. Presnell SR, Zhang L, Ramilo CA, Chan HW, Lutz CT. Functional redundancy of transcription factor-binding sites in the killer cell Ig-like receptor (KIR) gene promoter. Int Immunol. 2006;18:1221-1232.
49. Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods. 2008;44:205-221.
50. Lu Q, Zhang Y, Hu T, Guo P, Li W, Wang X. C. elegans Rab GTPase 2 is required for the degradation of apoptotic cells. Development. 2008;135:1069-1080.
51. Shen DT, Ma JS, Mather J, Vukmanovic S, Radoja S. Activation of primary T lymphocytes results in lysosome development and polarized granule exocytosis in CD4+ and CD8+ subsets, whereas expression of lytic molecules confers cytotoxicity to CD8+T cells. J Leukoc Biol. 2006;80:827-837.
52. Ma JS, Monu N, Shen DT, et al. Protein kinase C 8 regulates antigen receptor-induced lytic granule polarization in mouse CD8+ CTL. J Immunol. 2007;178:7814-7821.
53. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003; 281:65-78.
54. Peters PJ, Borst J, Oorschot V, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991;173:1099-1109.
55. Chan KS, Kaur A. Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. J Immunol Methods. 2007;325:20-34.
56. Balaji KN, Schasclike N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med. 2002;196:493-503.
57. Menager MM, Menasche G, Romao M, Knapnougel P, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMuncl3-4. Nat Immunol. 2007;8:257-267.
58. Smyth M.T, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000; 192: 755-760.
59. Muralitharan S, Wali YA, Dennison D, et al. Novel spectrum of perforin gene mutations in familial hemophagocytic lympho-histiocytosis in ethnic Omani patients. Am J Hematol. 2007;82: 1099-1102.
60. Voskoboinik I, Trapani JA. Addressing the mysteries of perforin function. Immunol Cell Biol. 2006;84:66-71.
61. Natarajan K, Cowan JA. Solution structure of a synthetic lytic peptide: the perforin amino terminus. Chem Biol. 1998; 5:147-154.
62. Ponting CP, Parker PJ. Extending the C2 domain family: C2s in PKCs 8, e, a, 6, phospholipases, GAPs, and perforin. Protein Sci. 1996;5:162-166.
63. Voskoboinik I, Thia MC, Fletcher J, et al. Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem. 2005; 280:8426-8434.
64. Uellner R, Zvelebil MJ, Hopkins J, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 1997;16:7287-7296.
65. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today. 1995;16:194-201.
66. Sauer H, Pratsch L, Tschopp J, Bhakdi S, Peters R. Functional size of complement and perforin pores compared by confocal laser scanning microscopy and fluorescence microphotolysis. Biochim Biophys Acta. 1991;1063:137-146.
67. Motyka B, Korbutt G, Pinkoski MJ, et al. Manose 6/phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell. 2000;103:491-500.
68. Trapani JA, Sutton VR, Thia KY, et al. A clatrhin/dynamic and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J Cell Biol. 2003;160:223-233.
69. Keefe D, Shi 1, Feske S, et al. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity. 2005;23:249-262.
70. Froelich CJ, Orth K, Turbov J, et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem. 1996;271:29073-29079.
71. Waterhouse NJ, Sedelies KA, Trapani JA. Role of bid-induced mitochondrial outer membrane permeabilization in granzyme B-induced apoptosis. Immunol Cell Biol. 2006;84:72-78.
72. Takata H, Takiguchi M. Three memory subsets of human CD8+ T cells differently expressing three cytolytic effector molecules. J Immunol. 2006;177:4330-4340.
73. Salvesen GS, Riedl SJ. Caspase mechanisms. Adv Exp Med Biol. 2008;615:13-23.
74. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003;112:659-672.
75. Zhang D, Beresford PJ, Greenberg AH, Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc Natl Acad Sci US A. 2001;98:5746-5751.
76. Chowdhury D, Beresford PJ, Zhu P, et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006;23:133-142.
77. Beresford PJ, Zhang D, Oh DY, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001;276: 43285-43293.
78. Martinvalet D, Zhu P, Lieberman J. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005;22:355-370.
79. Zhang D, Pasternack MS, Beresford PJ, Wagner L, Greenberg AH, Lieberman J. Induction of rapid histone degradation by the cytotoxic T lymphocyte protease Granzyme A. J Biol Chem. 2001;276:3683-3690.
80. Irmler M, Hertig S, MacDonald HR, et al. Granzyme A is an interleukin 1 β-converting enzyme. J Exp Med. 1995;181:1917-1922.
81. Sower LE, Klimpel GR, Hanna W, Froelich CJ. Extracellular activities of human granzymes. I. Granzyme A induces IL-6 and IL-8 production in fibroblast and epithelial cell lines. Cell Immunol. 1996;171:159-163.
82. Pinkoski MJ, Waterhouse NJ, Heiben JA, et al. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl2-inhibitable mitochondrial pathway. J Biol Chem. 2001; 276:12060-12067.
83. Metkar SS, Wang B, Ebbs ML, et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol. 2003;160:875-885.
84. Waterhouse NJ, Sedelies KA, Sutton VR, et al. Functional dissociation of SPsim and cytochrome c release defines the contribution of mitochondria upstream of caspase activation during granzyme B-induced apoptosis. Cell Death Differ. 2006;13:607-618.
85. Sutton VR, Waterhouse NJ, Browne KA, et al. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol. 2007; 176: 425-433.
86. Zhao T, Zhang H, Guo Y, Fan Z. Granzyme K directly processes Bid to release cytochrome C and endonulease G leading to mitochondria-dependent cell death. J Biol Chem. 2007;282: 12104-12111.
87. Andrade F, Fellows E, Jenne DE, Rosen A, Young CS. Granzyme H destroys the lime turn of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. EMBO J. 2007;26:2148-2157.
88. Kelly JM, Waterhouse NJ, Cretney E, et al. Granzyme M mediates a novel form of perforin-dependent cell death. J Biol Chem. 2004;279:22236-22242.
89. Bovenschen N, de Koning PJ, Quadir R, et al. NK cell protease granzyme M targets a-tubulin and disorganizes the microtubule network. J Immunol. 2008;180:8184-8191.
90. Kaiserman D, Bird CH, Sun J, et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol. 2006;175:619-630.
91. Latinovic-Golic S, Walch M, Sundstrom H, Dumrese C, Groscurth P, Ziegler U. Expression, processing and transcriptional regulation of granulysin in short-term activated human lymphocytes. BMC Immunol. 2007;8:9.
92. Kaspar AA, Okada S, Kumar J, et al. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol. 2001;167:350-356.
93. Walch M, Latinovic-Golic S, Velie A, et al. Perforin enhances the granulysm-induced lysis of listeria innocua in human dendritic cells. BCM Immunol. 2007;8:14.
94. Deng A, Chen S, Li Q, Lyu SC, Clayberger C, Krensky AM. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol. 2005;174:5243-5248.
95. Hidalgo LG, Einecke G, Allanach K, Halloran PF. The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4+ CTL, CD8+ CTL and NK cells. Am J Transplant. 2008;8:627-636.
96. Saigusa S, Ichikura T, Tsujimoto H, et al. Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma. J Gastroenterol Hepatol. 2007;22:1322-1327.
97. Bi LL, Pan G, Atkinson TP, et al. Dominant inhibition of fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) type lb. BMC Med Genet. 2007;8:41.
98. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology. 2004; 127: 1760-1774.
99. Ji J, Chen JJ, Braciale VL, Cloyd MW. Apoptosis induced in HIV-1-exposed, resting CD4+ T cells subsequent to signaling through homing receptors is Fas/Fas ligand-mediated. J Leukoc Biol. 2007;81:297-305.
100. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6:782-789.
101. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas Ligand (CD95L). Science. 1998;282:1714-1717.
102. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA. Identification of amino acid residues important for ligand binding to Fas. J Exp Med. 1997;185:1487-1492.
103. Henkler F, Behrle E, Dennehy KM, et al. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol. 2005;168:1087-1098.
104. Ramaswamy M, Siegel RM. A FAScinating receptor in self-tolerance. Immunity. 2007;26:545-547.
105. Sun M, Ames KT, Suzuki I, Fink PJ. The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol. 2006;177: 1481-1491.
106. Dzialo-Hatton R, Milbrandt J, Hockett RD Jr, Weaver CT. Differential expression of Fas ligand in Thl and Th2 cells is regulated by early growth response gene and NF-AT family members. J Immunol. 2001;166:4534-4542.
107. Gourley TS, Chang CH. Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J Immunol. 2001;166:2917-2921.
108. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19-26.
109. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med. 1999;5:90-96.
110. Zuccato E, Blott EJ, Holt O, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci. 2007;120:191-199.
111. Knox PG, Milner AE, Green NK, Eliopoulos AG, Young LS. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol. 2003;170:677-685.
112. Miyagawa-Hayashino A, Tsuruyama T, Egawa H, et al. FasL expression in hepatic antigen-presenting cells and phagocytosis of apoptotic T cells by FasL+ Kupffer cells are indicators of rejection activity in human liver allografts. Am J Pathol. 2007;171:1499-1508.
113. Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology. 2007; 120:133-139.
114. Carrington PE, Sandu C, Wei Y, et al. The structure of FADD and its mode of interaction with procaspase-8. Mol Cell. 2006; 22:599-610.
115. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490.
116. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
117. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
118. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111-113.
119. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997; 16:5386-5397.
120. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599-609.
121. Muppidi JR, Lobito AA, Ramaswamy M, et al. Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ. 2006;13:1641-1650.
122. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-l/Fas) signaling pathways. EMBO J. 1998;17:1675-1687.
123. Algeciras-Schimnich A, Peter ME. Actin dependent CD95 internalization is specific for Type I cells. FEBS Lett. 2003;546: 185-188.
124. Lee KH, Feig C, Tchikov V, et al. The role of receptor internalization in CD95 signaling. EMBO J. 2006;25:1009-1023.
125. Matarrese P, Manganelli V, Garofalo T, et al. Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem J. 2008; 413:467-478.
126. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem. 2007;282:12831-12841.
127. Kreuz S, Siegmund D, Rumpf JJ, et al. NFKB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol. 2004;166:369-380.
128. Vempati UD, Diaz F, Barrientos A, et al. Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor a is associated with respiratory defects but not with lack of cytochrome C release. Mol Cell Biol. 2007;27:1771-1783.
129. Strauss G, Knape I, Melzner I, Debatin KM. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated antigen-specific T cells. J Immunol. 2003;171:1172-1182.
130. Mtillbacher A, Lobigs M, Hla RT, Tran T, Stehle T, Simon MM. Antigen-dependent release of IFN-y by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J Immunol. 2002; 169: 145-150.
131. Cunningham TD, Jiang X, Shapiro DJ. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol. 2007;245:32-41.
132. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-160.
133. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15:24-27.
134. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell. 1993;73:431-445.
135. Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996;4:1251-1262.
136. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005;280:2205-2212.
137. Zhang X, Vallabhaneni R, Loughran PA, et al. Changes in FADD levels, distribution, and phosphorylation in TNFa-induced apoptosis in hepatocytes is caspase-3, caspase-8 and BID dependent. Apoptosis. 2008;13:983-992.
138. Chen H, Li M, Campbell RA, et al. Interference with nuclear factor K B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene. 2006;25: 6520-6527.
139. Manna SK, Haridas V, Aggarwal BB. Bcl-x(L) suppresses TNF-mediated apoptosis and activation of nuclear factor-KB, activation protein-1, and c-Jun N-terminal kinase. J Interferon Cytokine Res. 2000;20:725-735.
140. Chandel NS, Schumacker PT, Arch RH. Reactive oxygen species are downstream products of TRAF-mediated signal transduction. J Biol Chem. 2001;276:42728-42736.
141. Byun HS, Won M, Park KA, et al. Prevention of TNF-induced necrotic cell death by rottlerin through a Noxl NADPH oxidase. Exp Mol Med. 2008;40:186-195.
142. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Noxl NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell. 2007;26:675-687.